Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fludarabine + Carmustine + Melphalan
- Development stage
- Preclinical
- Lead developer
- Suzhou Hongci Hematology Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fludarabine + Carmustine + Melphalan (FBMA) is a reduced intensity conditioning (RIC) regimen used prior to allogeneic hematopoietic stem cell transplant in patients with myelogenous leukemia. This combination chemotherapy aims to suppress the patient's immune system to prevent graft rejection and to eradicate residual malignant cells, thereby preparing the bone marrow for the engraftment of donor stem cells.
- Other names
- FBMA方案
02
Targets
DNA
Beyond the preview
Go deeper on Fludarabine + Carmustine + Melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fludarabine + Carmustine + Melphalan.